BACKGROUND: Although ex vivo lung perfusion (EVLP) is increasingly being used to evaluate and manipulate potential donor lungs before lung transplantation (LTx), data on the biochemistry of lungs during EVLP are limited. In this study, we examined the physiology and biochemistry of human lungs on an EVLP circuit. METHODS: We recovered unallocated double lungs in standard fashion and split them into single lungs. All lungs received a nebulized arginase inhibitor, 2-S-amino-6-boronohexanoic acid (ABH), at either the onset (n = 6) or after 3 h (n = 8) of EVLP. Serial biochemical analysis included levels of arginase, endogenous nitric oxide synthase (eNOS), cyclic guanosine monophosphate, and reactive oxygen species. We considered lungs transplantable if they sustained a PaO2:FiO2 ≥ 350 in addition to stable pulmonary function during EVLP. RESULTS: We recovered a total of 14 single lungs. We deemed three single lungs from different donors to be transplantable after EVLP. These lungs had superior oxygenation, lower carbon dioxide, and more stable pulmonary artery pressures. Transplantable lungs had higher baseline levels of eNOS and higher final levels of cyclic guanosine monophosphate than non-transplantable lungs. Early ABH administration was associated with a transient increase in dynamic compliance. CONCLUSIONS: In this biochemical characterization of lungs deemed unsuitable for LTx, early levels of eNOS and late levels of cyclic guanosine monophosphate appear to be associated with improved allograft function during EVLP. In addition, nebulized ABH is associated with a significant increase in dynamic compliance. These data suggest that biochemical markers during EVLP may predict acceptable allograft function, and that this platform can be used to biochemically manipulate donor lungs before LTx.
BACKGROUND: Although ex vivo lung perfusion (EVLP) is increasingly being used to evaluate and manipulate potential donor lungs before lung transplantation (LTx), data on the biochemistry of lungs during EVLP are limited. In this study, we examined the physiology and biochemistry of human lungs on an EVLP circuit. METHODS: We recovered unallocated double lungs in standard fashion and split them into single lungs. All lungs received a nebulized arginase inhibitor, 2-S-amino-6-boronohexanoic acid (ABH), at either the onset (n = 6) or after 3 h (n = 8) of EVLP. Serial biochemical analysis included levels of arginase, endogenous nitric oxide synthase (eNOS), cyclic guanosine monophosphate, and reactive oxygen species. We considered lungs transplantable if they sustained a PaO2:FiO2 ≥ 350 in addition to stable pulmonary function during EVLP. RESULTS: We recovered a total of 14 single lungs. We deemed three single lungs from different donors to be transplantable after EVLP. These lungs had superior oxygenation, lower carbon dioxide, and more stable pulmonary artery pressures. Transplantable lungs had higher baseline levels of eNOS and higher final levels of cyclic guanosine monophosphate than non-transplantable lungs. Early ABH administration was associated with a transient increase in dynamic compliance. CONCLUSIONS: In this biochemical characterization of lungs deemed unsuitable for LTx, early levels of eNOS and late levels of cyclic guanosine monophosphate appear to be associated with improved allograft function during EVLP. In addition, nebulized ABH is associated with a significant increase in dynamic compliance. These data suggest that biochemical markers during EVLP may predict acceptable allograft function, and that this platform can be used to biochemically manipulate donor lungs before LTx.
Authors: S Fischer; A Matte-Martyn; M De Perrot; T K Waddell; Y Sekine; M Hutcheon; S Keshavjee Journal: J Thorac Cardiovasc Surg Date: 2001-03 Impact factor: 5.209
Authors: Marcelo Cypel; Jonathan C Yeung; Mingyao Liu; Masaki Anraku; Fengshi Chen; Wojtek Karolak; Masaaki Sato; Jane Laratta; Sassan Azad; Mindy Madonik; Chung-Wai Chow; Cecilia Chaparro; Michael Hutcheon; Lianne G Singer; Arthur S Slutsky; Kazuhiro Yasufuku; Marc de Perrot; Andrew F Pierre; Thomas K Waddell; Shaf Keshavjee Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: T Suda; B N Mora; F D'Ovidio; J A Cooper; M Hiratsuka; W Zhang; T Mohanakumar; G A Patterson Journal: J Thorac Cardiovasc Surg Date: 2000-02 Impact factor: 5.209
Authors: Jonathan C Yeung; Dirk Wagnetz; Marcelo Cypel; Matthew Rubacha; Terumoto Koike; Yi-Min Chun; Jim Hu; Thomas K Waddell; David M Hwang; Mingyao Liu; Shaf Keshavjee Journal: Mol Ther Date: 2012-03-27 Impact factor: 11.454
Authors: M Liu; L Tremblay; S D Cassivi; X H Bai; E Mourgeon; A F Pierre; A S Slutsky; M Post; S Keshavjee Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-05 Impact factor: 5.464
Authors: Timothy J George; George J Arnaoutakis; Claude A Beaty; Simran K Jandu; Lakshmi Santhanam; Dan E Berkowitz; Ashish S Shah Journal: J Surg Res Date: 2012-03-18 Impact factor: 2.192
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Morgan Salmon; Dustin Money; Sarah Schubert; Mark H Stoler; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: Ann Thorac Surg Date: 2017-04-21 Impact factor: 4.330
Authors: Matthew L Stone; Ashish K Sharma; Valeria R Mas; Ricardo C Gehrau; Daniel P Mulloy; Yunge Zhao; Christine L Lau; Irving L Kron; Mary E Huerter; Victor E Laubach Journal: Transplantation Date: 2015-12 Impact factor: 4.939
Authors: Anil Bhatta; Lin Yao; Zhimin Xu; Haroldo A Toque; Jijun Chen; Reem T Atawia; Abdelrahman Y Fouda; Zsolt Bagi; Rudolf Lucas; Ruth B Caldwell; Robert W Caldwell Journal: Cardiovasc Res Date: 2017-11-01 Impact factor: 10.787